Floatz logo

hdm2017

HER2 Positive Breast Cancer

Prestige Biopharma LimitedPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

188 Active assets in the HER2 Positive Breast Cancer cohort.

View all 50

Same molecule, other indications

hdm2017 is also rated in:

metastatic malignant neoplasm in the colonDormant
CC
Indicative ·
41 / 100
View asset →
neoplasmDormant
C
Indicative ·
37 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →